Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: UMLS:C0018799 (heart disease)
34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The proliferation of standard as well as novel community based systems for resuscitation of victims of out-of-hospital cardiac arrest has provided a large group of sudden cardiac death survivors who present a therapeutic challenge. The nature and severity of the underlying heart disease must be delineated. Particularly, myocardial ischemia and congestive heart failure must be controlled. Prior to considering device therapy of surgical intervention, pharmacologic therapy should be evaluated. Baseline electrophysiological studies determine the applicability of serial pharmacologic testing. In patients with inducible VT/VF, serial electrophysiological testing can identify drug regimens that prevent the arrhythmia in approximately 40% of patients. In an additional 20% of patients, regimens which slow the ventricular tachycardia and significantly reduce the arrhythmia related mortality can be identified. Three to 5-year follow-up has shown such an approach can reduce the sudden death mortality in these patients to less than 3% per year. It has been suggested that certain medication, most notably amiodarone, electrophysiological testing has not been useful in assessing efficacy. Several recent studies, however, have shown that electrophysiological testing is indeed useful even in evaluating the efficacy of amiodarone. In patients in whom ventricular tachycardia/ventricular fibrillation cannot be prevented or significantly slowed, medical therapy is generally ineffective and the sudden death mortality is 20% to 40% per year. In such patients, other therapeutic modalities should be considered.
...
PMID:Drug therapy for survivors of sudden cardiac death. 246 73

Catheter electrical ablation of ventricular tachycardia (VT) was attempted in 31 patients (57 +/- 15 years) who had refractory recurrent VT. Fifteen patients had coronary artery disease, seven had arrhythmogenic right ventricular dysplasia, four had cardiomyopathy and five had no structural heart disease. Ten patients were NYHA class III-IV. Ten patients experienced cardiac arrest or syncope during VT. Twenty-two patients had only one documented morphologic type of spontaneous VT. Whereas nine patients had more than one: the VT was incessant or daily in 17 patients. One to 16 shocks (mean 5.6) of 160 to 240 joules each (1162 +/- 1060 joules) were delivered to the endocardial exit site of VT--as identified by endocardial activation mapping (29 patients) and pacemapping (31 patients)--during one (22 patients) or more than one session (nine patients). Cumulative delivered energy was 840 +/- 558 joules for right ventricular VT (11 patients) and 1362 +/- 1240 joules for left ventricular VT (20 patients). Reversible side effects occurring immediately after shocks included: nonclinical VT (two patients), ventricular fibrillation (two patients), AV block (three patients). Mean CK-MB fraction 6 hours after shocks was 91 +/- 46 IU/1. An electrophysiology study performed 7 to 10 days later demonstrated that the original clinical VT was inducible in seven patients, nonclinical monomorphic VT was inducible in eight patients and no VT was inducible in 13 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Fulguration of ventricular tachycardia using high cumulative energy: results in thirty-one patients with a mean follow-up of twenty-seven months. 246 59

Along one year, cardiorespiratory resuscitation was done to 71 patients, aged 3 days to 10 years (median 3.5 month), in a pediatric intensive care unit. Although 39 patients (55%) recovered through first-stage treatment, in 17 the arrest was recurrent and they died in the following 24 hours. Only 12 (16.9%) children definitely survived. No patients requiring reanimation for more than 10 min, survived. Asystole was the most frequent arrhythmia (92%). There were only 4 cases of ventricular fibrillation, all occurred in patients with congenital heart disease, and no one recovered. Survivors have not evidence of neurological deficiencies, and only one died along one year follow up, because of congenital heart disease.
...
PMID:[Cardiorespiratory failure: results of resuscitation in a pediatric ICU]. 248 21

The authors analysed a series of 557 consecutive patients who suffered cardiorespiratory arrest at the Dante Pazzanese Institute of Cardiology (DPIC) during a period of 5 years in order to examine factors predicting successful resuscitation and long-term survival. Cardiopulmonary resuscitation (CPR) maneuvers were tried in 536 patients, with the following results: 284 patients (53%) died immediately, another 102 (19%) died within the first 24 h after the cardiac arrest and 150 patients (28%) survived more than 24 h. Among these, 65 (12.1%) died in the first month after cardiac arrest and other 29 (5.4%) died after that period. There were 43 late survivors (8%). Thirteen patients (2.4%) were lost to follow-up. After 9 years, the accumulative life expectancy was 8.7%. Coronary heart disease, cardiomyopathy and valvular heart disease were the most frequent underlying diseases. None of the 49 patients with cyanotic congenital heart disease survived. The heart arrest was mostly caused by heart failure (55.8%) and primary arrhythmia (17.2%) in the whole group, whereas the survivor group showed primary arrhythmia in 81.7% and heart failure in 7.3%. In those patients where the initial mechanism of cardiac arrest was ventricular fibrillation, 33.2% survived more than 1 month, while among those on ventricular asystole, only 3.4% survived more than 1 month.
...
PMID:Results of cardiopulmonary resuscitation in a cardiology hospital. 255 49

Since 1977, six patients (five males and one female), aged 14 to 35 years, resuscitated from ventricular fibrillation, were referred to our department for detailed evaluation, after exclusion of major cardiac pathologic conditions. Four patients had a family history of heart disease. Basic ECGs showed sinus rhythm in all of them. PR interval was prolonged in one. Two patients had complete and one had incomplete right bundle branch block. One patient had inverted t waves in V1-3 and late potentials. Three had an upsloping ST-T segment elevation in V1-2. The cardiothoracic index was less than 0.5 in five and 0.50 in one. In one of the five patients studied, the clinical episode of ventricular fibrillation was reproduced by stimulation of the right ventricular outflow tract during electrophysiologic study. Results of cross-sectional echocardiography and angiography showed predominantly structural and wall motion abnormalities of the right ventricle in five patients and slight wall motion abnormalities of the left ventricle in two. Two patients also had mitral and tricuspid valve prolapse. Coronary arteries were normal in all five patients examined. Results of endomyocardial biopsy showed no abnormalities in one patient, fibrosis in two, and fibrolipomatosis in one. Two patients died during follow-up: autopsy was performed in one and results showed right ventricular cardiomyopathy. Thus in five of these selected patients with apparent idiopathic ventricular fibrillation, some abnormalities, predominantly of the right ventricle, were documented only after detailed investigation; however, clinical history and some nonspecific ECG abnormalities were factors in the diagnostic procedure.
...
PMID:Ventricular fibrillation without apparent heart disease: description of six cases. 258 61

The clinical efficacy of intravenous amiodarone in terminating sustained ventricular tachycardia and in preventing recurrences of ventricular tachycardia and ventricular fibrillation was evaluated in 26 patients. All of them presented with organic heart disease accompanied by depressed left ventricular function. Intravenous amiodarone terminated spontaneous ventricular tachycardia in eight of 19 patients. Fifteen of the 26 patients had had at least one episode of ventricular tachycardia or ventricular fibrillation each day in the period immediately before the intravenous administration of amiodarone. Amiodarone controlled ventricular tachycardia or ventricular fibrillation in nine of these 15 patients; in three further cases it was successful when supplemented by additional administration of a previously ineffective antiarrhythmic drug and ventricular pacing. Two patients died despite these measures. In one, the amiodarone infusion had to be stopped because of an arrhythmogenic effect. Sustained deterioration of haemodynamic function or of pre-existing intraventricular conduction disturbances was never seen. Intravenous amiodarone was effective in terminating sustained ventricular tachycardia and in preventing frequent episodes of ventricular arrhythmia that were refractory to other antiarrhythmic drugs.
...
PMID:Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. 259 May 89

The purpose of this presentation is to report the first endocardial catheter ablation in Mexico of a right posteroseptal accessory pathway. The patient, without structural heart disease, had a Wolff Parkinson White syndrome with recurrent episodes of paroxysmal supraventricular tachycardia and atrial fibrillation with a fast ventricular response, through the accessory pathway (Shorter RR interval less than or equal to 190 msec). Previous antiarrhythmic drug therapy had failed to control the tachyarrhythmias. An electrophysiologic study was performed and the right posterior septal accessory pathway was localized by direct mapping of the auriculoventricular junction. Two sessions of electrofulguration with energy shocks ranging from 200 to 250 joules were delivered. There were no complications during the two procedures. Three months afterwards the patient is asymptomatic without tachyarrhythmic episodes, and no drug therapy is necessary. The fulguration prolonged the anterograde accessory pathway conduction. Therefore, the risk of sudden cardiac death due ventricular fibrillation has been reduced.
...
PMID:[Electrofulguration of a pre-excitation zone by the bundle of Kent]. 260 86

In 22 of 335 consecutive patients (6.6%) referred for evaluation and treatment of sustained ventricular tachyarrhythmias, hemodynamic and angiographic findings revealed no structural heart disease. Entry arrhythmia was ventricular fibrillation in 10 patients and sustained ventricular tachycardia in 12 patients. A subgroup of four young patients presented with slow recurrent (during 51 +/- 43 months) sustained ventricular tachycardias that were reproducibly terminated by intravenous application of verapamil. Programmed ventricular stimulation replicated the clinical arrhythmia in nine patients (75%) with ventricular tachycardia. In five patients (50%) with ventricular fibrillation no sustained ventricular arrhythmia could be induced, and only with three extrastimuli in four of the remaining five patients. On hospital discharge, 14 patients received type III antiarrhythmic agents, five patients received type I agents, and one patient received verapamil. Two patients were discharged without medical therapy. During the following 24 +/- 9 months, four patients had recurrent sustained ventricular tachycardia. No patient died suddenly during follow-up. We conclude that about 6% of all patients with ventricular tachyarrhythmias have apparently normal hearts. These idiopathic tachyarrhythmias seem to have a benign course, at least when treated. Slow, verapamil-sensitive tachycardias of young people may represent a unique entity.
...
PMID:[Continuous ventricular tachyarrhythmia in patients without detectable organic heart disease: clinical and electrophysiologic findings]. 262 22

The purpose of this study is to investigate the long-term prognosis of ventricular tachycardia (VT) mainly with respect to sudden death (SCD) in patients with ischemic heart disease (IHD), idiopathic cardiomyopathy (ICM), miscellaneous heart disease (MHD) and idiopathic ventricular tachycardia (IVT). The study included 117 patients with VT (80 male, 37 female). The number of patients with IHD, ICM, MHD and IVT were 40, 18, 26 and 33, respectively. Follow-up was conducted by means of a mailed standardized questionnaire. The mean follow-up period was 46.8 +/- 32.0 months (range from 6 to 125 months). In 24 out of the 117 patients the cause of death was SCD, in 9 there was no sudden cardiac death and in 5 no cardiac death. The other 76 were surviving. The number of SCD in IHD, ICM, MHD and IVT was 14/40 (35%), 4/17 (24%), 6/25 (24%) and zero (0%), respectively. The number of having had syncope in IHD, ICM, MHD and IVT was 19/40 (48%), 7/18 (39%), 6/26 (23%) and 6/33 (18%), respectively. Out of the 19 IHD patients with syncope, 15 had had ventricular fibrillation (VF). As for IVT with syncope, only one of the 6 had VF, which was induced by a disopyramide injection. In IVT, the patients with syncope had a significantly higher VT rate than those without syncope (p less than 0.01). There were no significant differences in the electrocardiographical high risk parameters for SCD, the age, follow-up periods, the presence or absence of VF and ejection fraction between the SCD and the surviving groups.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Long-term prognostic assessment of ventricular tachycardia with respect to sudden death in patients with and without overt heart disease. 263 26

Ventricular arrhythmias can be classified into categories based on the risk of sudden death associated with them. Patients with benign ventricular arrhythmias are those with minimal or no heart disease and normal ventricular function. Arrhythmias encountered in this group include ventricular premature complexes and unsustained ventricular tachycardia. In patients with prognostically significant ventricular arrhythmia, the arrhythmias are the same, namely, ventricular premature complexes and/or unsustained ventricular tachycardia. This group differs, however, in that the patients have organic heart disease and the risk of the arrhythmia increases as left ventricular function decreases. Patients with malignant ventricular arrhythmia, sustained ventricular tachycardia and ventricular fibrillation have the highest risk of sudden death. While no conclusive studies are available, some studies do suggest that the suppression of ambient ventricular arrhythmia as documented by Holter monitoring (and possibly exercise testing) identifies antiarrhythmic regimens which are effective in preventing sudden death. Variability in the frequency of ambient ventricular ectopy must be considered in assessing both efficacy and toxicity of antiarrhythmic regimens. Holter monitoring may also be useful in assessing the substrate of malignant ventricular arrhythmias and autonomic tone.
...
PMID:Ventricular arrhythmias: control of therapy by Holter monitoring. 268 May 3


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---